Exhibit 99.1
picture2.jpg
MariMed Reports First Quarter 2024 Earnings

NORWOOD, MA, May 8, 2024 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2024.
“With the first quarter now in the books, I’m pleased to say we are on track with our strategic plan and financial targets,” said Jon Levine, Chief Executive Officer. “The tremendous growth in our wholesale business was undoubtedly the highlight of the quarter. I am proud that once again, MariMed outperformed our competition in every market in which we operate, including Illinois. The strong revenue growth led to our 17th consecutive quarter of positive adjusted EBITDA.”
Financial Highlights1
The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts):
Three months ended
March 31,
2024
2023
Revenue$37.9 $34.4 
GAAP Gross margin43 %45 %
Non-GAAP Gross margin44 %46 %
GAAP Net loss
$(1.3)$(0.7)
Non-GAAP Net (loss) income
$(0.6)$0.3 
Non-GAAP Adjusted EBITDA$4.7 $7.1 
Non-GAAP Adjusted EBITDA margin12 %21 %
1 See the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures and additional information about non-GAAP measures in the section entitled “Discussion of Non-GAAP Financial Measures” below and in the financials information included herewith.
CONFERENCE CALL
MariMed management will host a conference call on Thursday, May 9, 2024 at 8:00 a.m. Eastern time, to discuss these results. The conference call may be accessed through MariMed’s Investor Relations website, or by clicking the following link: https://app.webinar.net/PYADonJoOrw.


FIRST QUARTER 2024 OPERATIONAL HIGHLIGHTS
During the first quarter, the Company announced the following developments in the implementation of its strategic growth plan:
•January 2: MariMed began selling its award-winning branded products through the Company's new wholesale business in Illinois. MariMed's brands, including Betty's Eddies, Bubby's Baked, Vibations, and InHouse are now widely available in 135 dispensaries throughout the state.
•February 26: Thrive Dispensary Casey, the adult-use dispensary MariMed managed since opening in Fall 2023, received its Certificate of Occupancy from the Illinois Cannabis Control Commission to commence operations in its permanent brick-and-mortar facility. The Company subsequently transitioned from its temporary facility and commenced operations in the new facility in March 2024.
•March 6: MariMed announced the expansion of its Maryland footprint with the acquisition of its second dispensary in the state. On February 1, the Company entered into a definitive agreement to acquire the operating assets of Our Community Wellness & Compassionate Care Center, Inc, a medical licensed dispensary operator. The Company subsequently announced the closing of the acquisition on April 9, and plans to open the dispensary, which is located in Upper Marlboro, and commence adult-use sales upon regulatory approval.
OTHER DEVELOPMENTS
Subsequent to the end of the first quarter, the Company announced the following further developments:
•April 10: MariMed announced a partnership with two iconic Boston music venues, MGM Music Hall Fenway and Citizens House of Blues Boston. This groundbreaking partnership positions Nature’s Heritage as the exclusive cannabis sponsor at each venue. The brand will receive over one million consumer impressions resulting from onsite fan experiences, in-venue advertising, and digital advertising.
•April 11: MariMed announced the closing of its acquisition of Thrive Dispensary in Casey, Illinois. The approval of the license transfer by the Illinois Department of Financial & Professional Regulation, and subsequent closing of the acquisition, allows MariMed to fully consolidate the financial results of this dispensary, which had previously been operated under a Managed Services Agreement.
2024 FINANCIAL GUIDANCE
MariMed's full year 2024 financial targets are based on organic growth of its existing operating assets and do not include new revenue-generating projects requiring regulatory approvals. The Company believes this conservative approach to offering financial targets allows investors and analysts to focus on key operating milestones versus discussions around issues outside the Company's control. As such, the Company's full year 2024 financial targets remain at:
•Revenue growth of 5% to 7%;
•Non-GAAP Adjusted EBITDA growth of 0% to 2%;
•Capital expenditures of $10 million.
DISCUSSION OF NON-GAAP FINANCIAL MEASURES
MariMed’s management uses several different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of its business, making operating decisions, and planning and forecasting future periods. The Company has provided in this release several non-


GAAP financial measures: Non-GAAP Gross margin, Non-GAAP Net income (loss), Non-GAAP Adjusted EBITDA and non-GAAP Adjusted EBITDA margin, as supplements to Revenue, Gross margin, Net income (loss) and other financial measures prepared in accordance with GAAP.
Management believes these non-GAAP financial measures are useful in reviewing and assessing the performance of the Company, and when planning and forecasting future periods, as they provide meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company’s management uses these non-GAAP financial measures to understand and compare operating results across accounting periods and for financial and operational decision-making. The presentation of these non-GAAP measures is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.
Management believes that investors and analysts benefit from considering non-GAAP financial measures in assessing the Company’s financial results and its ongoing business, as it allows for meaningful comparisons and analysis of trends in the business. In particular, non-GAAP adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.
As there are no standardized methods of calculating non-GAAP financial measures, the Company’s calculations may differ from those used by analysts, investors and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measures used by others.
Management defines non-GAAP Adjusted EBITDA as income (loss) from operations, determined in accordance with GAAP, excluding the following items:

•depreciation of fixed assets;
•amortization of acquired intangible assets;
•Impairment or write-downs of intangible assets;
•stock-based compensation;
•legal settlements; and
•acquisition-related and other expenses.
For further information, please refer to the publicly available financial filings available on MariMed's Investor Relations website, as filed with the U.S. Securities and Exchange Commission, or as filed with the Canadian securities regulatory authorities on the SEDAR website.
ABOUT MARIMED
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies, Nature’s Heritage, InHouse, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations, which are trademarks of MariMed Inc. For additional information, visit www.marimedinc.com.
IMPORTANT CAUTION REGARDING FORWARD-LOOKING STATEMENTS:
The information in this release contains “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties. All statements other than statements of historical facts contained in this release, including without


limitation statements regarding projected financial results for 2024, including management’s belief that it will report its fifth consecutive year of positive operating cash flow, anticipated openings of dispensaries and facilities, timing of regulatory approvals, plans and objectives of management for future operations, are forward-looking statements. Without limiting the foregoing, the words “anticipates”, “believes”, “estimates”, “expects”, “expectations”, “intends”, “may”, “plans”, and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on our current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, business prospects and strategic growth plan, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, our ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.
These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect our business and results of operations. These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional information regarding these and other factors can be found in our reports filed with the U.S. Securities and Exchange Commission. In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.
All trademarks and service marks are the property of their respective owners.
For More Information Contact:
Investor Relations:
Steve West, Vice President, Investor Relations
Email: ir@marimedinc.com
Phone: (781) 277-0007
Company Contact:
Howard Schacter, Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

# # #


MariMed Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
March 31,
2024		December 31,
2023
Assets  
Current assets:  
Cash and cash equivalents$15,234 $14,645 
Accounts receivable, net6,491 7,199 
Inventory29,044 25,306 
Deferred rents receivable612 630 
Notes receivable, current portion52 52 
Investments, current portion— 88 
Due from related parties181 105 
Other current assets3,281 3,407 
Total current assets54,895 51,432 
Property and equipment, net90,765 89,103 
Intangible assets, net12,819 17,012 
Goodwill15,812 11,993 
Investments, net of current portion274 221 
Notes receivable, net of current portion814 814 
Operating lease right-of-use assets9,456 9,716 
Finance lease right-of-use assets3,539 3,295 
Other assets12,958 12,537 
Total assets$201,332 $196,123 
   
Liabilities, mezzanine equity and stockholders’ equity
Current liabilities:
Mortgages and notes payable, current portion$1,057 $723 
Accounts payable10,256 9,001 
Accrued expenses and other4,613 3,549 
Income taxes payable16,271 14,434 
Operating lease liabilities, current portion1,955 1,945 
Finance lease liabilities, current portion1,303 1,210 
Total current liabilities35,455 30,862 
Mortgages and notes payable, net of current portion67,448 65,652 
Operating lease liabilities, net of current portion8,218 8,455 
Finance lease liabilities, net of current portion2,290 2,140 
Other liabilities100 100 
Total liabilities113,511 107,209 
  
Commitments and contingencies
  
Mezzanine equity  
Series B convertible preferred stock14,725 14,725 
Series C convertible preferred stock4,275 4,275 
Total mezzanine equity19,000 19,000 
  
Stockholders’ equity  
Common stock375 375 
Additional paid-in capital171,389 171,144 
Accumulated deficit(101,253)(99,955)
Noncontrolling interests(1,690)(1,650)
Total stockholders’ equity68,821 69,914 
Total liabilities, mezzanine equity and stockholders’ equity$201,332 $196,123 


MariMed Inc.
Condensed Consolidated Statements of Operations
(in thousands, except percentages and per share amounts)
(unaudited)
Three months ended
March 31,
20242023
Revenue$37,933 $34,380 
Cost of revenue21,461 18,992 
Gross profit16,472 15,388 
   
Gross margin43.4 %44.8 %
Operating expenses:
Personnel6,465 4,656 
Marketing and promotion1,762 1,146 
General and administrative6,140 4,305 
Acquisition-related and other84 190 
Bad debt— (44)
Total operating expenses14,451 10,253 
Income from operations2,021 5,135 
Interest and other (expense) income:
Interest expense(1,629)(2,505)
Interest income26 99 
Other expense, net(20)(900)
Total interest and other expense, net(1,623)(3,306)
Income before income taxes398 1,829 
Provision for income taxes1,690 2,493 
Net loss(1,292)(664)
Less: Net income (loss) attributable to noncontrolling interests6 (19)
Net loss attributable to common stockholders$(1,298)$(645)
Net loss per share attributable to common stockholders:
Basic$(0.00)$(0.00)
Diluted$(0.00)$(0.00)
Weighted average common shares outstanding:  
Basic375,211 342,794 
Diluted375,211 342,794 


MariMed Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Three months ended
March 31,
20242023
Cash flows from operating activities:
Net loss attributable to common stockholders$(1,298)$(645)
Net income (loss) attributable to noncontrolling interests6 (19)
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Depreciation and amortization of property and equipment1,938 986 
Amortization of intangible assets374 557 
Stock-based compensation244 208 
Amortization of original debt issuance discount— 55 
Amortization of debt discount87 328 
Amortization of debt issuance costs18 — 
Payment-in-kind interest14 118 
Present value adjustment of notes payable— 719 
Bad debt income— (44)
Obligations settled with common stock1 1 
Write-off of disposed assets1 906 
Gain on finance lease adjustment— (13)
Loss on changes in fair value of investments121 20 
Changes in operating assets and liabilities:
Accounts receivable, net707 (132)
Deferred rents receivable18 18 
Inventory(3,738)(3,246)
Other current assets391 639 
Other assets63 19 
Accounts payable1,334 (1,961)
Accrued expenses and other1,091 (207)
Income taxes payable1,838 (2,806)
Net cash provided by (used in) operating activities3,210 (4,499)
  
Cash flows from investing activities:
Purchases of property and equipment(3,368)(3,052)
Business acquisitions, net of cash acquired— (2,995)
Advances toward future business acquisitions(485)(300)
Purchases of investments(86)— 
Purchases of cannabis licenses(265)(601)
Proceeds from notes receivable13 43 
Due from related party(75)(20)
Net cash used in investing activities(4,266)(6,925)
   
Cash flows from financing activities:
Proceeds from term loan— 29,100 


Three months ended
March 31,
20242023
Proceeds from Construction to Permanent Commercial Real Estate Mortgage Loan1,047 — 
Proceeds from mortgages1,163 — 
Principal payments of mortgages(65)(203)
Principal payments of promissory notes(135)(9)
Repayment and retirement of promissory notes— (5,503)
Principal payments of finance leases(320)(69)
Distributions(45)(34)
Net cash provided by financing activities1,645 23,282 
  
Net increase in cash and cash equivalents589 11,858 
Cash and equivalents, beginning of year14,645 9,737 
Cash and cash equivalents, end of period$15,234 $21,595 


MariMed Inc.
Reconciliation of Non-GAAP and GAAP Financial Measures
(in thousands, except percentages)
(unaudited)

 Three months ended
March 31,
 20242023
Non-GAAP Adjusted EBITDA
GAAP Income from operations$2,021 $5,135 
Depreciation and amortization of property and equipment1,938 986 
Amortization of acquired intangible assets374 557 
Stock-based compensation244 206 
Acquisition-related and other84 190 
Adjusted EBITDA$4,661 $7,074 
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)
GAAP Income from operations5.3 %14.9 %
Depreciation and amortization of property and equipment5.2 %2.9 %
Amortization of acquired intangible assets1.0 %1.6 %
Stock-based compensation0.6 %0.6 %
Acquisition-related and other0.2 %0.6 %
Adjusted EBITDA margin12.3 %20.6 %

GAAP Gross margin43.4 %44.8 %
Amortization of acquired intangible assets0.4 %0.8 %
Non-GAAP Gross margin43.8 %45.6 %


GAAP Net loss$(1,292)$(664)
Amortization of acquired intangible assets374 557 
Stock-based compensation244 206 
Acquisition-related and other84 190 
Non-GAAP Net (loss) income$(590)$289 


MariMed Inc.
Supplemental Information
Revenue Components
(in thousands)
(unaudited)
Three months ended
March 31,
20242023
Product revenue:
Product revenue - retail22,346 23,183 
Product revenue - wholesale14,505 10,376 
Total product revenue36,851 33,559 
Other revenue1,082 821 
Total revenue$37,933 $34,380